Contributions of each of the BAFF receptors to the lymphocyte profiles in C57BL/6 mice.
B cells
BAFF
BAFF receptors
Foxp3+ T cells
Journal
Immunology
ISSN: 1365-2567
Titre abrégé: Immunology
Pays: England
ID NLM: 0374672
Informations de publication
Date de publication:
31 Aug 2024
31 Aug 2024
Historique:
received:
27
03
2024
accepted:
18
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
31
8
2024
Statut:
aheadofprint
Résumé
BAFF, a vital B cell survival and differentiation factor, has three receptors: B-cell maturation antigen (BCMA), transmembrane activator and CAML interactor (TACI) and BR3. Although B cells are greatly reduced in B6.Baff
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Selena Gomez Fund
Informations de copyright
© 2024 The Author(s). Immunology published by John Wiley & Sons Ltd.
Références
Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, et al. BAFF binds to the tumor necrosis factor receptor‐like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med. 2000;192(1):129–135.
Do RKG, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen‐Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192(7):953–964.
Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40‐independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002;3(9):822–829.
Rolink AG, Tschopp J, Schneider P, Melchers F. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol. 2002;32(7):2004–2010.
Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190(11):1697–1710.
Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B‐cell autoimmune disease. Nature. 2000;404(6781):995–999.
Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, et al. Severe B cell hyperplasia and autoimmune disease in TALL‐1 transgenic mice. Proc Natl Acad Sci U S A. 2000;97(7):3370–3375.
Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga‐Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA‐independent pathway. Science. 2001;293(5537):2111–2114.
Laabi Y, Gras MP, Brouet JC, Berger R, Larsen CJ, Tsapis A. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 1994;22(7):1147–1154.
von Bülow GU, Bram RJ. NF‐AT activation induced by a CAML‐interacting member of the tumor necrosis factor receptor superfamily. Science. 1997;278(5335):138–141.
Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, et al. BAFF‐R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293(5537):2108–2111.
Yan MH, Brady JR, Chan B, Lee WP, Hsu B, Harless S, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001;11(19):1547–1552.
Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Investig. 2003;112(2):286–297.
Yang M, Hase H, Legarda‐Addison D, Varughese L, Seed B, Ting AT. B cell maturation antigen, the receptor for a proliferation‐inducing ligand and B cell‐activating factor of the TNF family, induces antigen presentation in B cells. J Immunol. 2005;175(5):2814–2824.
Darce JR, Arendt BK, Wu XS, Jelinek DF. Regulated expression of BAFF‐binding receptors during human B cell differentiation. J Immunol. 2007;179(11):7276–7286.
Benson MJ, Dillon SR, Castigli E, Geha RS, Xu SL, Lam KP, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol. 2008;180(6):3655–3659.
Goenka R, Matthews AH, Zhang B, O'Neill PJ, Scholz JL, Migone TS, et al. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med. 2014;211(1):45–56.
Xu SL, Lam KP. B‐cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol. 2001;21(12):4067–4074.
O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long‐lived bone marrow plasma cells. J Exp Med. 2004;199(1):91–97.
von Bülow GU, van Deursen JM, Bram RJ. Regulation of the T‐independent humoral response by TACI. Immunity. 2001;14(5):573–582.
Yan MH, Wang M, Chan B, Roose‐Girma M, Erickson S, Baker T, et al. Activation and accumulation of B cells in TACI‐deficient mice. Nat Immunol. 2001;2(7):638–643.
Seshasayee D, Valdez P, Yan MH, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity. 2003;18(2):279–288.
Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt‐Supprian M. TNF family member B cell‐activating factor (BAFF) receptor‐dependent and ‐independent roles for BAFF in B cell physiology. J Immunol. 2004;173(4):2245–2252.
Shulga‐Morskaya S, Dobles M, Walsh ME, Ng LG, MacKay F, Rao SP, et al. B cell‐activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell‐independent antibody formation. J Immunol. 2004;173(4):2331–2341.
Stohl W, Yu N, Wu Y. B cell and T cell dissimilarities in BAFF‐deficient versus BR3‐deficient C57BL/6 mice. J Immunol. 2022;209:2133–2140.
Jacob CO, Yu N, Guo SH, Jacob N, Quinn WJ, Sindhava V, et al. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum. 2013;65(4):1043–1054.
Stohl W, Yu N. Promotion of T regulatory cells in mice by B cells and BAFF. J Immunol. 2020;204(9):2416–2428.
Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, Bhan AK, et al. Impaired IgA class switching in APRIL‐deficient mice. Proc Natl Acad Sci U S A. 2004;101(11):3903–3908.
Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, et al. Enforced BCL2 expression in B‐lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A. 1991;88(19):8661–8665.
Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune‐based rheumatic diseases. J Immunol. 2002;169(8):4314–4321.
Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, et al. B‐lymphocyte stimulator/a proliferation‐inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B‐cell maturation antigen‐immunoglobulin. Arthritis Res Ther. 2010;12(2):R48.
Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, et al. Reduced competitiveness of autoantigen‐engaged B cells due to increased dependence on BAFF. Immunity. 2004;20(4):441–453.
Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self‐reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785–798.
Hao Y, O'Neill P, Naradikian MS, Scholz JL, Cancro MP. A B‐cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood. 2011;118(5):1294–1304.
Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, et al. Toll‐like receptor 7 (TLR7)‐driven accumulation of a novel CD11c+ B‐cell population is important for the development of autoimmunity. Blood. 2011;118(5):1305–1315.
Stohl W, Yu N, Chalmers S, Putterman C, Jacob CO. Development of murine systemic lupus erythematosus in the absence of BAFF. Arthritis Rheumatol. 2020;72(2):292–302.
Tardivel A, Tinel A, Lens S, Steiner QG, Sauberli E, Wilson A, et al. The anti‐apoptotic factor Bcl‐2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur J Immunol. 2004;34(2):509–518.
Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 2005;52(7):2080–2091.
Jiang C, Loo WM, Greenley EJ, Tung KS, Erickson LD. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J Immunol. 2011;186(11):6136–6147.
Kayagaki N, Yan MH, Seshasayee D, Wang H, Lee W, French DM, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF‐κB2. Immunity. 2002;17(4):515–524.
Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al. TACI‐Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15(2):289–302.
Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S, et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med. 2001;194(11):1691–1697.
Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus‐prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006;177(4):2671–2680.
Coquery CM, Loo WM, Wade NS, Bederman AG, Tung KS, Lewis JE, et al. BAFF regulates follicular helper T cells and affects their accumulation and interferon‐γ production in autoimmunity. Arthritis Rheumatol. 2015;67(3):773–784.
Marsters SA, Yan MH, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol. 2000;10(13):785–788.
Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, et al. APRIL and TALL‐I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2000;1(3):252–256.
Wu YM, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem. 2000;275(45):35478–35485.
Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000;192(11):1677–1683.
Huard B, Schneider P, Mauri D, Tschopp J, French LE. T cell costimulation by the TNF ligand BAFF. J Immunol. 2001;167(11):6225–6231.
Ng LG, Sutherland APR, Newton R, Qian F, Cachero TG, Scott ML, et al. B cell‐activating factor belonging to the TNF family (BAFF)‐R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173(2):807–817.
Sutherland APR, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST, et al. BAFF augments certain Th1‐associated inflammatory responses. J Immunol. 2005;174(9):5537–5544.
Stohl W, Wu Y, Stohl M. T cell dissimilarities in BAFF‐deficient versus BR3‐deficient SLE‐prone NZM 2328 mice as contributors to their divergent clinical outcomes. ACR Open Rheumatology. 2024. https://doi.org/10.1002/acr2.11712
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930.
Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo‐controlled, phase 3 trial. Lancet. 2011;377(9767):721–731.
Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty‐two‐week randomized, double‐blind, placebo‐controlled study. Arthritis Rheumatol. 2017;69(5):1016–1027.
Zhang FC, Bae SC, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo‐controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77(3):355–363.